Sutro Biopharma (STRO) closed at $10.61 on November 9, 2026, up 10.3% from the previous close, on volume of 254,072 shares (30-day average 304,770).
Data as of November 9, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 23, 2026 | Call Spread | 21-May-2710 : 20 C | 216 |
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 9, 2026. See the 10 largest for 30, 60 and 90 days
Sutro Biopharma to Participate in Upcoming Investor Conferences
Globe Newswire (Wed, 4-Nov 8:00 AM ET)
Globe Newswire (Wed, 21-Oct 8:00 AM ET)
Sutro Biopharma highlights STRO-004 safety and dual-payload STRO-227 at World ADC Conference
Market Chameleon (Tue, 13-Oct 7:09 AM ET)
Sutro Biopharma Announces Participation at the 17th Annual World ADC Conference
Globe Newswire (Mon, 12-Oct 8:00 AM ET)
Sutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business Development
Globe Newswire (Tue, 29-Sep 8:00 AM ET)
Globe Newswire (Wed, 12-Aug 7:00 AM ET)
Market Chameleon (Tue, 10-Feb 4:41 AM ET)
Sutro Biopharma Advances STRO-004 with First Patients Dosed in Pioneering Phase 1 Study
Market Chameleon (Thu, 4-Dec 5:03 AM ET)
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
Sutro Biopharma trades on the NASDAQ stock market under the symbol STRO.
As of November 10, 2026, STRO stock price declined to $10.17 with 212,923 million shares trading.
STRO has a beta of 2.28, meaning it tends to be more sensitive to market movements. STRO has a correlation of 0.09 to the broad based SPY ETF.
STRO has a market cap of $168.49 million. This is considered a Micro Cap stock.
Last quarter Sutro Biopharma reported $10 million in Revenue and -$2.33 earnings per share. This fell short of revenue expectation by $-1 million and missed earnings estimates by -$.11.
In the last 3 years, STRO traded as high as $61.30 and as low as $5.23.
The top ETF exchange traded funds that STRO belongs to (by Net Assets): VTI, IWM, VXF, FESM, VTWO.
STRO has outperformed the market in the last year with a price return of +24.6% while the SPY ETF gained +12.9%. However, in the short term, STRO had mixed performance relative to the market. It has underperformed in the last 3 months, returning -59.9% vs -2.8% return in SPY. But in the last 2 weeks, STRO shares have fared better than the market returning +14.5% compared to SPY -2.0%.
STRO support price is $9.90 and resistance is $11.32 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that STRO shares will trade within this expected range on the day.
